Efficacy and Safety of Prophylactic Tocilizumab in Patients with Multiple Myeloma Receiving Bispecific Antibodies: A Systematic Review and Meta-Analysis.

A pooled analysis of two studies evaluating grade ≥2 cytokine release syndrome showed a numerically lower risk with prophylaxis, although this did not reach statistical significance (RR 0.22, 95% CI 0.02-2.57; p = 0.23).

Cytokine release syndrome events were predominantly low grade, short-lived, and occurred during step-up dosing.

ICANS was uncommon, and infection and hematologic toxicity rates were comparable between groups.

No signal of reduced overall response rate was observed (RR 1.21, 95% CI 0.91-1.62; p = 0.19).